INDUSTRY
BLOGS

By early 2026, Denmark's connection queue for new large-scale power projects had reached roughly 60 gigawatts, against a peak national demand of around 7 gigawatts. In March 2026, Energinet, the state grid operator, paused new large-load connection agreements. It was the first hard stop of its kind in the Nordic region.

What has followed is a full legislative overhaul.

New York, Texas and North Carolina have each taken regulatory action against data centre growth within the space of a few weeks. New York's governor signed an executive order in July pausing state permits for large data centres for up to a year while regulators build a formal environmental review process.[1] Texas ordered a full audit of every data centre project in ERCOT's interconnection queue in August, halting new approvals until agencies can verify what those projects actually need and how they plan to get it.[2] North Carolina's state budget repealed the sales tax exemption on electricity that qualifying data centres had relied on for two decades, while leaving capital investment incentives in place.[3]

These are three different mechanisms. Permitting, grid oversight and tax policy each work differently and sit with different agencies. But the timing is worth paying attention to. Three states have reached for three separate levers within weeks of each other, and that pattern says more about where the industry is heading than any one action does on its own.

JLL 's midyear 2026 North America Data Center Report found that 77 percent of the current construction pipeline now sits in what it calls frontier markets, Texas, Ohio, Louisiana, and the Carolinas. Places that, until recently, had little to no data centre development history. Demand has doubled year-over-year, absorption hit a record 25GW in the first half of the year alone, and 66GW of capacity is now under construction, 95 percent of it already pre-committed. Vacancy has held at 1 percent for three straight years despite that pace of build. [1]

Eli Lilly and Company's new $5 billion facility in Goochland County, Virginia will be the company's first fully integrated site built specifically for its antibody-drug conjugate and bioconjugate portfolio.[1] Roche's $50 billion US investment includes a gene therapy facility in Pennsylvania the company is calling a center of excellence.[2] [3] AstraZeneca's own $50 billion commitment includes new cell therapy manufacturing facilities in Rockville, Maryland and Tarzana, California.[4]

Three of the largest pharma companies in the world are pouring capital into advanced therapy manufacturing at the same time, and all three are will be pulling from the same scarce talent pool once the buildings are finished.

Earlier this year, Nscale le secured $6.2 billion to build a data centre in a valley outside Narvik, in the Arctic north of Norway. The site was originally reserved for OpenAI 's Stargate capacity. Microsoft has since taken up that space instead, bringing 30,000 NVIDIA Rubin GPUs to a location chosen for its cheap renewable power, natural cooling and long-term energy contracts. Months on from that announcement, the project has become one of the clearest examples of a much bigger regional shift: the Nordics have become one of the most active data centre markets in Europe, and the momentum behind it keeps building.